The company is currently addressing NYSE listing compliance issues and continues to seek a suitable business combination target primarily in healthcare.

• On February 6, 2026, the company received a notice from the NYSE for non-compliance with the minimum public shareholder requirement [S2].
• The company submitted a plan on March 19, 2026, to regain compliance, which the NYSE accepted on April 29, 2026, allowing continued listing through August 6, 2027, subject to progress under the plan [S2].
• The company has not yet selected a target business for its initial combination and continues to evaluate acquisition candidates primarily in healthcare services and technology [S1].

The company benefits from a management team with deep healthcare industry and acquisition experience, which may enable it to identify and execute a value-creating business combination. Its substantial IPO proceeds held in trust provide capital to pursue acquisitions. The focus on healthcare, a sector with favorable macro dynamics and potential for operational improvements, aligns with management's expertise. The company’s plan to regain NYSE listing compliance indicates active management of regulatory requirements. Post-combination, the company aims to leverage public capital markets access and experienced management to support growth and value creation.

The company currently has no operating revenues and has incurred losses since inception, relying on capital markets and loans for funding. It faces significant competition from other SPACs and investors with greater resources, which may limit acquisition opportunities. Conflicts of interest may arise due to management's relationships with affiliated entities competing for deals. The company is under a NYSE plan to regain compliance with shareholder minimums, and failure to maintain listing could adversely affect liquidity and capital access. The absence of a selected target business and the broad discretion in applying IPO proceeds add uncertainty to execution.

As a blank check company, Jackson Acquisition Co II's moat is primarily derived from its management team's extensive experience and network in the healthcare industry and capital markets, which may provide access to acquisition opportunities and operational expertise post-combination. However, the company faces competition from other SPACs and investors with potentially greater resources and local knowledge. Its ability to secure attractive acquisition targets depends on its financial resources, management's discretion, and the competitive landscape. The company's structure as a SPAC means it currently has no operating business or revenue, limiting inherent competitive advantages until a business combination is completed.

• NYSE Listing Compliance Risk: The company is currently under a plan to regain compliance with NYSE listing standards, specifically the minimum public shareholder requirement. Failure to meet these requirements could lead to delisting, reduced liquidity, and limited capital market access [S2].
• Competition Risk: The company faces intense competition from other SPACs, private investors, and entities with greater resources and local industry knowledge, which may limit its ability to acquire attractive target businesses [S1].
• Conflicts of Interest: Certain officers and directors have fiduciary or contractual duties to affiliated entities that may compete for acquisition opportunities, potentially limiting the company’s access to deals [S1].
• Liquidity Risk: As of June 30, 2026, the company has limited liquidity outside the trust account, with a current ratio below 1, which may constrain operational flexibility [S2].
• Execution Risk: The company has not yet selected a target business for its initial combination, and broad management discretion in applying proceeds introduces execution uncertainty [S1].

• Jackson Acquisition Co II is a blank check company incorporated in the Cayman Islands on September 11, 2024, formed to effect a business combination with one or more businesses or entities, primarily focusing on healthcare services, healthcare technology, or healthcare industry-related businesses [S1].
• The company completed its IPO on December 11, 2024, issuing 23,000,000 units at $10.00 per unit, raising gross proceeds of $230 million, plus a private placement of 840,000 units raising $8.4 million, with total proceeds of $232.3 million placed in a trust account for the benefit of public shareholders and underwriters [S1].
• Management has broad discretion over the use of IPO and private placement proceeds held in the trust account, primarily intended for consummating a business combination and working capital [S1].
• Since IPO, the company has had no revenue and has incurred losses from formation and operating costs, funding operations through securities sales and loans from the sponsor and others [S1].
• The company’s Class A ordinary shares and rights trade on the NYSE under symbols JACS and JACS.R respectively, with public units trading as JACS.U [S1].
• The company’s acquisition strategy focuses on identifying fundamentally healthy companies with strong management teams, significant growth potential, clear value propositions, and readiness to access public capital markets, primarily in healthcare but not restricted to it [S1].
• Management and board have extensive experience in operating, growing, and acquiring companies, especially in healthcare services, and in accessing capital markets and executing value-creation plans [S1].
• The company’s initial business combination must meet NYSE listing rules, including acquiring at least 80% fair market value of assets held in trust, and must be approved by a majority of independent directors [S1].
• The company is an emerging growth company and smaller reporting company, eligible for certain reduced disclosure and compliance requirements [S1].
• As of June 30, 2026, the company reported current assets of $444,333 and current liabilities of $576,434, resulting in a current ratio of 0.77 and a cash ratio of 0, indicating limited liquidity outside the trust account [S2].
• Net income reported for the period ending June 30, 2026, was $1,980,048 [S2].
• Basic and diluted earnings per share were both -$0.01 as of September 30, 2024 [S2].
• The company received a notice from the NYSE on February 6, 2026, for non-compliance with the listing standard requiring at least 300 public shareholders, and submitted a plan accepted by the NYSE on April 29, 2026, allowing continued listing subject to progress under the plan through August 6, 2027 [S2].
• The company faces competition from other blank check companies, private investors, and entities with greater resources and local industry knowledge, which may limit its ability to acquire certain target businesses [S1].
• Conflicts of interest may arise as some officers and directors have fiduciary or contractual duties to related entities that may compete for acquisition opportunities [S1].